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1. Abbreviations 
The following abbreviations are used in the text of the Supplementary Information: anti-parallel 
(ap), aqueous (aq.), argon (Ar), bis(pinacolato)diboron (b(pin)2), di-tert-butyl dicarbonate 
(Boc2O), broad (br.), closed form (CF), 3-chloroperbenzoic acid (m-CPBA), diarylethene (DAE), 
dichloromethane (DCM), 4-(N,N-dimethylamino)pyridine (DMAP), N,N-dimethylformamide 
(DMF), dimethyl sulfoxide (DMSO), degree of labeling (DOL), 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC), electrospray ionization (ESI), ethyl acetate (EtOAc), 
ethanol (EtOH), high performance liquid chromatography (HPLC), high resolution mass 
spectrometry (HR-MS), potassium acetate (KOAc), N-hydroxysuccinimide (NHS), nuclear 
magnetic resonance (NMR), open form (OF), parallel (p), phosphate buffer saline (PBS), reverse 
phase (RP), room temperature (r.t.), saturated (sat.), 2-dicyclohexylphosphino-2′,6′-
dimethoxybiphenyl (SPhos), triethylamine (TEA), tetrahydrofurane (THF), trifluoroacetic acid 
(TFA), thin layer chromatography (TLC), ultraviolet (UV), visible (vis). 
2. Synthesis 
2.1    Liquid chromatography  
The following columns (cartridges) and solvent systems were used for analytical and preparative 
separations. System A: RP-HPLC (Eurosphere II, 100-5 C18 column, 5 µm, 4.0×150 mm) with 
CH3CN and 0.05% aq. TFA (pH ~ 2.0) [linear gradient from 30% to 70% of CH3CN in 20 min] 
at a flow rate of 1.2 mL/min; UV-vis detection with diode array and at 254 nm (OF) and 460 nm 
(CF). System B: automated flash purification on Biotage Isolera One (ISO-1EW) device 
(cartridge PF-C18-HC, 30 µM, with 20 g of RP-C18 silica gel) with the following eluent: 0.1% aq. 
TFA / CH3CN, 7:3, at a flow rate of 20 mL/min for 15 min; UV detection at 254 nm. System C: 
System A with a linear gradient from 60% to 90% of CH3CN in 15 min at a flow rate of 1.2 
mL/min. System D: System B with the following eluent: 0.1% aq. TFA / CH3CN, 3:7, at a flow 
rate of 20 mL/min for 15 min. System E: System B with the following eluent: 0.1% aq. TFA / 
CH3CN, 1:1, at a flow rate of 20 mL/min for 15 min. System F: RP-HPLC (Eurosphere II, 100-5 
C18 column, 5 µm, 4.0×150 mm) with CH3CN and 0.1% aq. TFA (pH ~ 1.5) [30% ACN: 0 – 3 
min, then linear gradient from 30% to 100% of CH3CN in 12 min] at a flow rate of 1.2 mL/min; 




2.2     Preparation of boronic esters 
Scheme S1. Preparation of pinacol ester of 3,5-di(tert-butoxycarbonyl)-4-methoxyphenylboronic acid. 
Di-tert-butyl 5-bromo-2-methoxyisophthalate (S1) 
 
To a solution of 5-bromo-2-methoxyisophtalic acid
1
 (300 mg, 1.10 mmol) and DMAP (27 mg, 
0.22 mmol, 0.2 equiv.) in a mixture of DCM (5 mL) and DMF (0.2 mL), Boc2O (720 mg, 3.30 
mmol, 3 equiv.) was added in one portion, and stirred at reflux overnight. Then, the resulting 
mixture was washed thrice with a sat. NaHCO3 solution (3×35 mL), brine (50 mL), dried over 
MgSO4 and concentrated under vacuum. The residue was purified by flash chromatography on a 
silica gel (n-hexane/EtOAc, with a gradient from 100:0 to 90:10) to afford the title compound S1 
as viscous colorless oil (327 mg, 77% yield). Rf (n-hexane/EtOAc, 9:1, v/v) = 0.8. 
1
H NMR (400 
MHz, CDCl3): δ = 7.86 (s, 2 H), 3.89 (s, 3 H), 1.59 (s, 18 H). 
13
C NMR (101 MHz, CDCl3): δ = 















3,5-Di(tert-butoxycarbonyl)-4-methoxyphenylboronic acid pinacol ester (C) 
 
In a sealed tube purged with Ar, compound S1 (300 mg, 0.78 mmol), bis-pinacolato diboron 
(b(pin)2; 237 mg, 0.93 mmol, 1.2 equiv.), KOAc (23 mg, 2.40 mmol, 3 equiv.), Pd(dppf)Cl2 (19 
mg, 23 µmol, 0.03 equiv.) were combined, and dry 1,4-dioxan (5 mL) was added. The reaction 
mixture was purged with Ar for further 5 min (Ar bubbling) and stirred at reflux (bath temp. 
80 °C) for 2 h. After removal of volatile materials in vacuum, EtOAc (30 mL) was added, and 
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the reaction mixture was washed with brine (2×30 mL), dried over Na2SO4, concentrated under 
reduced pressure and subjected to column chromatography on silica gel (n-hexane/EtOAc, with a 
gradient from 100:0 to 70:30) to afford the boronic pinacol ester C as a white solid (201 mg, 
60% yield). Rf (n-hexane/EtOAc, 4:1, v/v) = 0.8. 
1
H NMR (400 MHz, CDCl3): δ = 8.13 (s, 2 H), 
3.90 (s, 3 H), 1.59 (s, 18 H), 1.33 (s, 12 H). 
13
C NMR (101 MHz, CDCl3): δ = 165.8, 160.4, 
139.9 (overlap of 2 signals), 128.3, 84.3, 82.0, 63.5, 28.3, 25.0. ESI-MS, positive mode: m/z (rel. 
int., %) = 457.1 (100) [M+Na]
+





Scheme S2. Pinacolato 3,5-bis[N,N-di-(tert-butoxycarbonylmethyl)]carbamoyl-4-methoxyphenyl boronate. 
Tetra-tert-butyl 5-bromo-2-methoxybenzene 1,3-bis-(carbonyl-N-iminodiacetate) 
(S2) 
 
To a solution of 5-bromo-2-methoxyisophthalic acid
1
 (552 mg, 2.0 mmol), SOCl2 (1.5 mL, 20.0 
mmol, 10 equiv.) and few drops of DMF were added, and the reaction mixture was refluxed 
overnight with stirring. An excess of thionyl chloride was removed by distillation, the residue co-
evaporated twice with DCM was used directly in the next step. This acyl chloride was dissolved 
in 35 mL of dry DCM, and a solution of TEA (0.81 mL, 6.0 mmol, 3 equiv.) and di-tert-butyl 
iminodiacetate
2
 (1.03 g, 4.2 mmol, 2.1 equiv.) was added dropwise at 0 °C. After stirring 
overnight at r.t., the mixture was filtered, the filtrate was washed thrice with a saturated aq. 
solution of NaHCO3 (3×35 mL), dried over MgSO4, concentrated under reduced pressure and 
subjected to flash chromatography on silica gel (n-hexane/EtOAc, with a gradient from 100:0 to 
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80:20). The title compound S2 was isolated as a white solid (1.0 g, 69% yield). Rf (n-
hexane/EtOAc, 7:3, v/v) = 0.67. 
1
H NMR (400 MHz, CDCl3): δ = 7.43 (s, 2 H), 4.54 (m, 2 H), 
3.90 (m, 9 H), 1.48 (s, 18 H), 1.42 (s, 18 H). 
13
C NMR (101 MHz, CDCl3): δ =167.6, 167.4, 
164.4, 133.4, 132.4, 130.4, 115.7, 82.4, 82.3, 51.7, 50.6, 47.7, 28.2, 28.1. ESI-MS, positive 































In a sealed tube purged with Ar, compound S2 (300 mg, 0.41 mmol), bis-pinacolato diboron 
(b(pin)2; 125 mg, 0.50 mmol, 1.2 equiv.), KOAc (121 mg, 1.23 mmol, 3 equiv.), and Pd(dppf)Cl2 
(10 mg, 12 µmol, 0.03 equiv.) were combined in dry 1,4-dioxan (5 mL). The reaction mixture 
was purged with Ar for 5 min (Ar bubbling) and stirred at reflux (bath temp. 80 °C) for 4 h. 
After removal of volatile materials in vacuum, EtOAc (30 mL) was added, and the reaction 
mixture was washed with brine (2×30 mL), dried over Na2SO4, concentrated under reduced 
pressure and subjected to column chromatography on silica gel (n-hexane/EtOAc, with a 
gradient from 100:0 to 70:30) to afford the title compound E as a white solid (186 mg, 58% 
yield). Rf (n-hexane/EtOAc, 7:3, v/v) = 0.51. 
1
H NMR (400 MHz, CDCl3): δ = 7.72 (s, 2 H), 4.53 
(m, 2 H), 3.93 (m, 9 H), 1.47 (s, 18 H), 1.40 (s, 18 H), 1.23 (s, 12 H). 
13
C NMR (101 MHz, 
CDCl3): δ = 169.6, 168.0, 137.2, 136.3, 128.7, 127.4, 84.0, 82.6, 82.0, 51.7, 47.9, 28.2, 28.1, 
methyl signals of pinacol residue are masked by strong singlets of tert-butyl groups. ESI-MS, 
positive mode: m/z (rel. int., %) = 799.7 (100) [M+Na]
+










To a solution of 1,2-bis(2-methyl-6-iodobenz[a]thiophen-1,1-dioxide-3-
yl)perfluorocyclopentene
3
 (123 mg, 0.16 mmol) in a mixture of Toluene/EtOH (3.5 mL, 6:1, 
v/v), (p-methoxyphenyl)boronic acid (68 mg, 0.45 mmol, 2.8 equiv.), Na2CO3 solution (2 M, 0.2 
mL, 2.5 equiv.), and Pd(PPh3)4 (9 mg, 7.80 µmol, 5 mol %) were added; the suspension was 
purged for 5 min with Ar (Ar “bubbling”) and stirred 12 h at reflux (bath temperature = 100 °C). 
After cooling down, the reaction mixture was filtered through a pad of Silica, washed with Et2O, 
and concentrated under reduced pressure. The residue was then purified by flash chromatography 
on silica gel (n-hexane/EtOAc, with a gradient from 90:10 to 70:30) to afford compound 3 as a 
red solid (53 mg, 45% yield). The closed isomer (≈ 10%) is produced during the preparation of 
this dye (see NMR spectra). ap:p = 55:45. 
1
H NMR (400 MHz, CDCl3): δ = 7.93 (s, 1.1 H, ap), 
7.88 (s, 0.9 H, p), 7.75 (d, J = 8.0 Hz, 1.1 H, ap), 7.59 (d, J = 8.0 Hz, 0.9 H, p), 7.53 (d, J = 8.5 
Hz, 2.2 H, ap), 7.45 (d, J = 8.5 Hz, 1.8 H, p), 7.21 (s, 1.1 H, ap), 7.19 (s, 0.9 H, p), 7.03 (d, J = 
8.5 Hz, 2.2 H, ap), 6.96 (d, J = 8.5 Hz, 1.8 H, p), 3.87 (s, 3.3 H, ap), 3.84 (s, 2.7 H, p), 2.23 (s, 
2.8 H, p), 2.09 (s, 3.2 H, ap). 
13
C NMR (126 MHz, CDCl3): δ = 160.6 ap, 160.6 p, 144.2 ap, 
144.0 p, 143.0 p, 142.8 ap, 136.1 ap, 136.1 p, 131.6 ap, 131.4 p, 130.5 ap, 130.5 p, 128.4 ap, 
128.4 p, 127.5 p, 127.3 ap, 124.1 ap, 124.0 p, 122.9 ap, 122.8 p, 121.0 ap, 120.9 p, 114.9 ap, 
114.8 p, 55.6 p/ap, 9.1 ap, 9.0 p. 
19
F NMR (376 MHz, CDCl3): δ = -109.86 (m, 4.0 F, p/ap), -
131.97 (m, 2.0 F, p/ap). HR-MS (ESI, positive mode): 762.1388 [M+NH4]
+
 (found), 762.1413 





2.4 Asymmetric DAEs  
S4a, R1 = Me
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Scheme S4. Synthesis of asymmetric DAEs as “tetra- and octa-acids”
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General Procedure A1 (GP A1): “the first Suzuki-Miyaura cross-coupling” 
To a solution of 1,2-bis(2-alkyl-6-iodobenz[a]thiophen-3-yl)perfluorocyclopentene
3-4
 (1 equiv., 
amount: 0.1 – 0.2 mmol) in a mixture of THF/H2O (4 mL, 3:1, v/v), arylboronic ester (1 equiv.), 
K3PO4 (3 equiv.), SPhos (0.1 equiv.) and Pd(dba)2 (0.1 equiv.) were added; the suspension was 
purged for 5 min with Ar (Ar “bubbling”) and stirred 4 h at reflux (bath temperature = 80 °C). 
Then, the reaction mixture was diluted with EtOAc, washed with brine (3 × 25 mL), dried over 
Na2SO4 and concentrated under reduced pressure. The residue was purified by flash 
chromatography on silica gel (n-hexane/EtOAc) to afford the desired “mono-substituted 
monoiodide” DAE as a purple viscous semi-solid. 
General Procedure A2 (GP A2): “the second Suzuki-Miyaura cross-coupling” 
To a solution of “mono-substituted monoiodide” (GP A1) (amount: 20 - 70 µmol) in a mixture of 
THF/H2O (4 mL, 3:1, v/v), arylboronic ester (3 equiv.), K3PO4 (3 equiv.), SPhos (0.1 equiv.) and 
Pd(dba)2 (0.095 equiv.) were added; the suspension was purged for 5 min with Ar (Ar 
“bubbling”) and stirred 4 h at reflux (bath temperature = 80 °C). Then, the reaction mixture was 
diluted with EtOAc, washed with brine (3 × 25 mL), dried over Na2SO4 and concentrated under 
reduced pressure. The residue was purified by flash chromatography on silica gel (n-
hexane/EtOAc) to afford the desired asymmetric DAE as a white solid. 
General Procedure B (GP B): “Benzothiophene oxidation” 
To a solution of asymmetric DAE (GP A2) (amount: 10 - 40 µmol) in DCM (2 mL), m-CPBA (9 
equiv.) was added, and the reaction mixture was stirred 24 h at r.t. Then the reaction mixture was 
diluted with DCM, washed with a sat. NaHCO3 solution (20 mL), brine (35 mL), dried over 
MgSO4, and concentrated under reduced pressure. The residue was purified by flash 
chromatography on silica gel (n-hexane/EtOAc) to afford the desired oxidized compound as an 
orange solid. 
General Procedure C (GP C): “Cleavage of tert-butyl esters” 
The oxidized DAE (amount: 10 - 30 µmol) was dissolved in a mixture of TFA/DCM (4 mL, 1:1, 
v/v) and stirred for 1 h at reflux. Then the reaction mixture was concentrated in vacuum and 
subjected to flash chromatography using a RP-C18 cartridge. The product-containing fractions 








The synthesis of this diiodide DAE was performed according to a published procedure
5
. Iodine 
(258 mg, 1.02 mmol, 0.9 equiv.) and H5IO6 (35 mg, 0.39 mmol, 0.35 equiv.) was added to a 
stirred solution of 1,2-bis(2-ethyl-benz[a]thiophen-3-yl)perfluorocyclopentene (560 mg, 1.13 
mmol) in AcOH (37.5 mL), H2SO4 (750 µL), and water (1.8 mL), and the mixture was stirred for 
3 h at 70 °C in the open air. The reaction mixture was poured into 100 mL of ice-water, diluted 
with EtOAc (100 mL), washed with a sat. solution of NaHCO3 and brine, dried over MgSO4, and 
concentrated under reduced pressure. The residue was purified by column chromatography on 
silica gel (100 % n-hexane) to afford the “diiodo-sulfide” DAE as a white solid (306 mg, 36%). 
ap:p = 60:40. This compound was used in the next step without further purification (purity over 
85% determined by NMR). Rf (n-hexane) = 0.40. HR-MS (ESI, negative mode): 746.8599 [M-
H]
-















Compound S4a was synthesized from 1,2-bis(2-methyl-6-iodobenz[a]thiophen-3-
yl)perfluorocyclopentene
3
 (100 mg, 0.14 mmol) according to GP A1, and purified by column 
chromatography on silica gel gel (n-hexane/EtOAc, with a gradient from 100:0 to 90:10); 43 mg, 
36% yield. This compound was used in the next step without further purification (purity over 
85% determined by NMR). Rf (n-hexane/EtOAc, 9:1, v/v) = 0.30. HR-MS (ESI, positive mode): 
893.0659 [M+Na]
+









Compound S4b was synthesized from 1,2-bis(2-ethyl-6-iodobenz[a]thiophen-3-
yl)perfluorocyclopentene
4
 (120 mg, 0.16 mmol) according to GP A1, and purified by column 
chromatography on silica gel gel (n-hexane/EtOAc, with a gradient from 100:0 to 90:10); 60 mg, 
42% yield. This compound was used in the next step without further purification (purity over 
85% determined by NMR). Rf (n-hexane/EtOAc, 9:1, v/v) = 0.35. HR-MS (ESI, positive mode): 
921.0963 [M+Na]
+





Compound S5a was synthesized from compound S4a (43 mg, 0.049 mmol) according to GP A2, 
and purified by column chromatography on silica gel gel (n-hexane/EtOAc, with a gradient from 
100:0 to 80:20); 26 mg, 62% yield. Rf (n-hexane/EtOAc, 9:1, v/v) = 0.24. ap:p = 65:35. 
1
H NMR 
(400 MHz, CDCl3): δ = 8.57 (br. t, J = 1.6 Hz, 0.6 H, ap), 8.52 (br. t, J = 1.6 Hz, 0.4 H, p), 8.41 
(d, J = 1.6 Hz, 1.2 H, ap), 8.31 (d, J = 1.6 Hz, 0.8 H, p), 7.98 (d, J = 1.6 Hz, 0.6 H, ap), 7.88 (d, J 
= 1.6 Hz, 0.4 H, p), 7.86 (d, J = 1.6 Hz, 0.6 H, ap), 7.78 – 7.39 (m, 6.4 H, p/ap), 7.00 (d, J = 8.6 
Hz, 1.2 H, ap), 6.93 (d, J = 8.6 Hz, 0.8 H, p), 3.86 (s, 1.9 H, ap), 3.82 (s, 1.1 H, p), 2.54 (s, 1.0 
H, p), 2.52 (s, 1.0 H, p), 2.28 (s, 2.0 H, ap), 2.26 (s, 2.0 H, ap), 1.65 (s, 12.0 H, ap), 1.61 (s, 6.0 
H, p). 
13
C NMR (101 MHz, CDCl3): δ = 165.1, 159.4, 159.4, 144.0, 143.5, 142.8, 141.0, 139.2, 
139.2, 138.1, 137.6, 137.1, 136.1, 133.2, 133.1, 133.0, 131.9, 130.6, 129.4, 129.3, 129.1, 128.5, 
128.4, 128.4, 124.3, 124.2, 124.1, 122.7, 122.7, 122.5, 122.4, 122.2, 120.8, 120.6, 120 0, 119.8, 
119.4, 119.2, 119.1, 114.5, 114.5, 114.4, 82.0, 81.9, 55.5, 55.5, 28.3, 28.3, 15.5, 15.4. 
19
F NMR 
(376 MHz, CDCl3): δ = -110.0 (m, 4.0 F, p/ap), -132.8 (m, 2.0 F, p/ap). HR-MS (ESI, positive 
mode): 873.2126 [M+Na]
+







Compound S5b was synthesized from compound S4b (60 mg, 0.067 mmol) according to GP A2, 
and purified by column chromatography on silica gel gel (n-hexane/EtOAc, with a gradient from 
100:0 to 80:20); 36 mg, 61% yield. Rf (n-hexane/EtOAc, 9:1, v/v) = 0.32. ap:p = 60:40. 
1
H NMR 
(400 MHz, CDCl3): δ = 8.57 (br. t, J = 1.6 Hz, 0.6 H, ap), 8.52 (br. t, J = 1.6 Hz, 0.4 H, p), 8.41 
(d, J = 1.6 Hz, 1.2 H, ap), 8.31 (d, J = 1.6 Hz, 0.8 H, p), 8.01 (d, J = 1.6 Hz, 0.6 H, ap), 7.90 (d, J 
= 1.6 Hz, 0.4 H, p), 7.88 (d, J = 1.6 Hz, 0.6 H, ap), 7.80 – 7.39 (m, 6.4 H, p/ap), 6.99 (d, J = 8.8 
Hz, 1.2 H, ap), 6.93 (d, J = 8.8 Hz, 0.8 H, p), 3.86 (s, 2.2 H, ap), 3.82 (s, 0.8 H, p), 2.96 (m, 0.6 
H, p/ap), 2.77 (m, 2.0 H, p/ap), 2.50 (m, 1.4 H, p/ap), 1.65 (s, 12.0 H, ap), 1.61 (s, 6.0 H, ap), 
1.34 (m, 2.4 H, p), 0.87 (m, 3.6 H, ap). 
13
C NMR (101 MHz, CDCl3): δ = 165.1, 165.1, 159.5, 
159.4, 151.8, 151.2, 150.6, 150.1, 143.5, 141.1, 141.0, 139.1, 139.1, 139.0, 138.9, 138.2, 137.9, 
137.6, 137.5, 137.1, 136.9, 136.0, 134.9, 133.2, 133.2, 133.1, 133.0, 131.9, 131.9, 130.6, 129.4, 
129.4, 129.3, 129.3, 129.1, 128.5, 128.5, 128.4, 128.4, 125.6, 124.3, 124.2, 124.1, 124.0, 122.7, 
122.7, 122.4, 122.4, 122.3, 120.9, 120.8, 120.1, 120.0, 118.1, 117.9, 117.8, 114.5, 114.4, 82.0, 
81.9, 55.5, 55.5, 28.3, 28.3, 23.6, 23.5, 23.3, 23.2, 16.1, 16.1, 15.6, 15.6. 
19
F NMR (376 MHz, 
CDCl3): δ = -110.3 (m, 4.0 F, p/ap), -132.7 (m, 2.0 F, p/ap). HR-MS (ESI, positive mode): 
901.2389 [M+Na]
+





Compound S6a was synthesized from S5a (26 mg, 0.031 mmol) according to GP B, and purified 
by column chromatography on silica gel gel (n-hexane/EtOAc, with a gradient from 100:0 to 
80:20); 21 mg, 75% yield. Rf (n-hexane/EtOAc, 4:1, v/v) = 0.35. ap:p = 50:50. 
1
H NMR (400 
MHz, CDCl3): δ = 8.63 (s, 0.5 H, ap), 8.58 (s, 0.5 H, p), 8.35 (d, J = 1.6 Hz, 1.0 H, ap), 8.27 (d, 
J = 1.6 Hz, 1.0 H, p), 8.01 - 7.85 (m, 3.0 H, p/ap), 7.76 (dd, J = 1.6 Hz and 7.7 Hz, 0.5 H, p), 
7.71 (dd, J = 1.6 Hz and 7.7 Hz, 0.5 H, ap), 7.64 – 7.39 (m, 3.0 H, p/ap), 7.20 (d, J = 8.0 Hz, 1.0 
H, p/ap), 7.00 (d, J = 8.0 Hz, 1.0 H, p), 6.95 (d, J = 8.0 Hz, 1.0 H, ap), 3.87 (s, 1.5 H, ap), 3.83 
(s, 1.5 H, p), 2.26 (s, 1.5 H, p), 2.23 (s, 1.5 H, p), 2.12 (s, 1.5 H, ap), 2.10 (s, 1.5 H, ap), 1.65 (s, 
9.0 H, ap), 1.61 (s, 9.0 H, p). 
13
C NMR (101 MHz, CDCl3): δ = 164.6, 160.6, 144.5, 144.3, 
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144.1, 143.9, 143.6, 142.8, 142.6, 138.5, 136.3, 136.1, 134.8, 133.9, 133.6, 133.5, 132.6, 132.4, 
131.6, 131.6, 131.5, 131.5, 130.8, 130.8, 130.5, 130.4, 130.0, 129.1, 128.9, 128.4, 128.4, 127.5, 
127.3, 124.0, 123.8, 123.1, 122.9, 122.7, 121.7, 121.5, 121.1, 120.9, 114.9, 114.8, 82.4, 55.6, 
28.3, 14.3, 14.3. 
19
F NMR (376 MHz, CDCl3): δ = -109.6 (m, 4.0 F, p/ap), -132.0 (m, 2.0 F, 
p/ap). HR-MS (ESI, positive mode): 937.1917 [M+Na]
+






Compound S6b was synthesized from S5b (35 mg, 0.040 mmol) according to GP B, and purified 
by column chromatography on silica gel gel (n-hexane/EtOAc, with a gradient from 100:0 to 
80:20); 18 mg, 50% yield. Rf (n-hexane/EtOAc, 4:1, v/v) = 0.28. ap:p = 55:45. 
1
H NMR (400 
MHz, CDCl3): δ = 8.63 (br. t, J = 1.5 Hz, 0.6 H, ap), 8.58 (br. t, J = 1.5 Hz, 0.4 H, p), 8.35 (d, J = 
1.6 Hz, 1.2 H, ap), 8.27 (d, J = 1.6 Hz, 0.8 H, p), 8.04 - 7.85 (m, 3 H, p/ap), 7.77 (dd, J = 1.8 and 
8.0 Hz, 0.6 H, ap), 7.70 (dd, J = 1.8 and 8.0 Hz, 0.4 H, p), 7.64 – 7.39 (m, 3 H, p/ap), 7.24 (d, J 
= 7.4 Hz, 0.6 H, ap), 7.24 (d, J = 7.4 Hz, 0.4 H, p), 7.01 (d, J = 8.8 Hz, 1.2 H, ap), 6.95 (d, J = 
8.8 Hz, 0.8 H, p), 3.87 (s, 1.7 H, ap), 3.83 (s, 1.3 H, p), 2.63 (m, 2.8 H, p/ap), 2.45 (m, 1.2 H, 
p/ap), 1.64 (s, 11 H, ap), 1.61 (s, 7 H, p), 1.43 (m, 2.7 H, p), 1.11 (m, 3.3 H, ap). 
13
C NMR (101 
MHz, CDCl3): δ = 164.7, 164.7, 160,6, 160.6, 149.1, 148.8, 148.2, 147.8, 4144.3, 144.2, 142.8, 
142.7, 138.5, 138.5, 136.8, 136.8, 136.6, 136.6, 134.8, 134.0, 133.6, 133.5, 132.5, 132.2, 131.6, 
131.6, 131.3, 131.1, 130.8, 130.8, 130.5, 130.5, 130.4, 130.0, 129.0, 128.9, 128.5, 128.4, 128.4, 
127.4, 127.3, 123.5, 123.4, 123.3, 123.2, 122.9, 121.3, 120.6, 114.9, 114.8, 82.4, 82.4, 55.6, 55.5, 
28.3, 28.3, 19.5, 19.4, 19.4, 19.3, 12.1, 12.0, 11.9, 11.8. 
19
F NMR (376 MHz, CDCl3): δ = -109.9 
(m, 4.0 F, p/ap), -132.1 (m, 2.0 F, p/ap). HR-MS (ESI, positive mode): 965.2202 [M+Na]
+
 





Compound 7-Me was synthesized from S6a (21 mg, 0.023 mmol) according to GP C, and 





H NMR (400 MHz, DMF-d7): δ = 8.71 (br. t, J = 1.6 Hz, 0.5 H, p), 8.66 (m, 1.0 H, p/ap), 
8.62 (m, 1.0 H, p/ap), 8.60 (d, J = 1.6 Hz, 0.5 H, ap), 8.54 (m, 1.0 H, p/ap), 8.37 (d, J = 1.6 Hz, 
0.5 H, p), 8.31 (m, 1.0 H, p/ap), 8.17 (m, 1.0 H, p/ap), 8.02 (m, 1.5 H, p/ap, masked by the signal 
of the residual CH-protons in DMF-d7), 7.89 (m, 2.0 H, p/ap), 7.76 (m, 1.0 H, p/ap), 7.12 (d, J = 
8.8 Hz, 1.0 H, ap), 7.05 (d, J = 8.8 Hz, 1.0 H, p), 3.89 (s, 1.2 H, p), 3.85 (s, 1.8 H, ap), 2.39 (s, 
1.5 H, p), 2.38 (s, 1.5 H, p), 2.32 (s, 3.0 H, ap). 
13
C NMR (126 MHz, DMF-d7): δ = 167.8, 167.8, 
162.0, 161.9, 145.5, 144.8, 143.5, 143.4, 140.3, 140.2, 137.4, 137.3, 135.0, 134.7, 134.1, 134.0, 
133.4, 133.4, 133.2, 131.7, 131.3, 129.9, 129.9, 128.3, 125.8, 125.7, 125.5, 124.6, 124.5, 123.0, 
122.8, 121.6, 121.5, 116.0, 115.9, 56.5, 56.5, 9.8, 9.5. 
19
F NMR (376 MHz, DMF-d7): δ = -109.2 
(m, 4.0 F, p/ap), -130.2 (m, 2.0 F, p/ap). HR-MS (ESI, negative mode): 801.0671 [M-H]
-
 
(found), 801.0693 (calculated for C38H23F6O9S2, [M-H]
-
). HPLC (system C): tR = 9.3 min (93% 
HPLC area, open form); 11.5 min (1% HPLC area, closed form). 
Compound 7-Et 
 
Compound 7-Et was synthesized from S6b (18 mg, 0.019 mmol) according to GP C, and 
purified by flash chromatography using a RP-C18 cartridge (system D); 9 mg, 57% yield. ap:p = 
60:40. 
1
H NMR (500 MHz, DMF-d7): δ = 8.71 (br. t, J = 1.6 Hz, 0.6 H, ap), 8.66 (m, 0.8 H, p), 
8.63 (d, J = 1.6 Hz, 0.6 H, ap), 8.56 (d, J = 1.6 Hz, 0.4 H, p), 8.54 (d, J = 1.6 Hz, 0.6 H, p), 8.37 
(d, J = 1.8 Hz, 0.6 H, ap), 8.34 (d, J = 1.8 Hz , 0.4 H, p), 8.33 (d, J = 1.8 Hz , 0.4 H, p), 8.25 (d, J 
= 1.8 Hz, 0.6 H, p), 8.18 (m, 1.0 H, p/ap), 8.02 (m, 2.0 H, p/ap, overlaps with the signal of the 
residual CH-protons in DMF-d7), 7.89 (m, 2 H, p/ap), 7.76 (m, 1.0 H, p/ap), 7.13 (d, J = 9.7 Hz, 
1.2 H, ap), 7.05 (d, J = 9.7 Hz, 0.8 H, p), 3.90 (s, 1.8 H, ap), 3.85 (s, 1.2 H, p), 2.82 (m, 2.4 H, 
p/ap), 2.64 (m, 1.6 H, p/ap), 1.41 (m, 2.6 H, p), 1.08 (m, 3.4 H, ap). 
13
C NMR (126 MHz, DMF-
d7): δ = 167.5, 167.5, 161.7, 161.6, 150.5, 150.2, 149.4, 149.3, 144.7, 144.7, 143.4, 143.3, 140.0, 
139.9, 137.6, 137.5, 137.5, 137.3, 134.7, 134.3, 133.8, 133.7, 133.1, 133.1, 132.9, 131.4, 131.4, 
131.0, 130.9, 129.6, 129.6, 129.6, 129.5, 128.0, 127.8, 126.1, 125.8, 125.6, 124.1, 124.0, 122.4, 
122.2, 121.0, 120.9, 115.7, 115.6, 56.2, 56.2, 20.1, 20.0, 20.0, 19.9, 12.8, 12.7, 12.6, 12.4. 
19
F 
NMR (471 MHz, DMF-d7): δ = -109.8 (m, 4.0 F, p/ap), -130.7 (m, 2.0 F, p/ap). HR-MS (ESI, 
positive mode): 853.0956 [M+Na]
+
 (found), 853.0971 (calculated for C40H28F6NaO9S2, 
[M+Na]
+
). HPLC (system B): tR = 10.8 min (91% HPLC area, open form); 12.5 min (1% HPLC 





Compound S7 was synthesized from S4b (42 mg, 48.2 µmol) according to GP A2, and purified 
by column chromatography on silica gel gel (n-hexane/EtOAc, with a gradient from 100:0 to 
80:20); 28 mg, 54% yield. Rf (n-hexane/EtOAc, 9:1, v/v) = 0.20. ap:p = 65:35. 
1
H NMR (400 
MHz, CDCl3): δ = 8.55 (bt, J = 1.6 Hz, 0.6 H, ap), 8.50 (bt, J = 1.6 Hz, 0.4 H, p), 8.40 (d, J = 1.6 
Hz, 1.2 H, ap), 8.31 (d, J = 1.6 Hz, 0.8 H, p), 8.03 - 7.99 (m, 2.0 H, p/ap), 7.96 - 7.91 (m, 2.0 H, 
p/ap), 7.85 – 7.60 (m, 3.0 H, p/ap), 7.50 (dd, J = 1.8 Hz & 8.5 Hz, 0.6 H, ap), 7.43 (dd, J = 1.8 
Hz & 8.5 Hz, 0.4 H, ap), 3.95 (s, 1.0 H, p), 3.94 (s, 2.0 H, ap), 2.95 (m, 0.6 H, p/ap), 2.78 (m, 
2.0 H, p/ap), 2.50 (m, 1.4 H, p/ap), 1.64 (m, 38.4 H, p/ap), 0.88 (t, J = 6.6 Hz, 3.6 H, ap). 
13
C 
NMR (101 MHz, CDCl3): Due to co-elution of this compound with the starting boronic ester 
(compound C), it was not possible to interpret the 
13
C NMR spectrum. 
19
F NMR (376 MHz, 
CDCl3): δ = -110.2 (m, 4.0 F, p/ap), -130.7 (m, 2.0 F, p/ap). ESI-MS, negative mode: m/z (rel. 
int., %) = 465.7 (100) [M-2H+K]
-
 (found), 465.5 (calculated for C42H27KF6O9S2, [M-2H+K]
-
, 
premature cleavage of tert-butyl substituents occurred during this analysis). 
Compound S8 
 
Compound S8 was synthesized from compound S7 (28 mg, 25.9 µmol) according to GP B, and 
purified by column chromatography on silica gel gel (n-hexane/EtOAc, with a gradient from 
100:0 to 80:20); 18 mg, 60% yield. Rf (n-hexane/EtOAc, 9:1, v/v) = 0.15. ap:p = 60:40. 
1
H NMR 
(400 MHz, CDCl3): δ = 8.62 (bt, J = 1.6 Hz, 0.6 H, ap), 8.58 (bt, J = 1.6 Hz, 0.4 H, p), 8.35 (d, J 
= 1.6 Hz, 1.2 H, ap), 8.27 (d, J = 1.6 Hz, 0.8 H, p), 8.10 - 7.95 (m, 4.0 H, p/ap), 7.92 - 7.86 (m, 
1.4 H, p/ap), 7.82 (dd, J = 1.7 and 8.0 Hz, 0.6 H, ap), 7.72 (dd, J = 1.8 and 8.0 Hz, 0.4 H, p), 
7.66 (dd, J = 1.8 and 8.0 Hz, 0.4 H, p), 7.59 (m, 1.2 H, p/ap), 3.96 (s, 1.8 H, ap), 3.91 (s, 1.2 H, 
p), 2.62 (m, 2.7 H, p/ap), 2.45 (m, 1.3 H, p/ap), 1.65 (s, 11.0 H, ap), 1.63 (s, 11.0 H, ap), 1.60 (s, 
7.0 H, p), 1.58 (s, 7.0 H, p), 1.44 (m, 2.6 H, p), 1.11 (m, 3.4 H, ap). 
13
C NMR (101 MHz, 
CDCl3): δ = 165.0, 165.0, 164.7, 164.6, 159.1, 159.0, 149.2, 149.0, 148.8, 148.8, 142.8, 142.7, 
142.5, 142.4, 138.5, 138.4, 136.8, 136.8, 134.8, 133.9, 133.6, 133.5, 133.2, 133.2, 132.5, 132.3, 
132.2, 132.1, 132.0, 131.6, 131.6, 130.9, 130.8, 130.4, 130.0, 129.8, 129.6, 129.0, 128.8, 128.6, 
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128.5, 123.4, 123.3, 123.1, 123.0, 121.3, 121.3, 121.0, 121.0, 82.8, 82.7, 82.4, 82.4, 63.8.63.7, 
28.3, 28.3, 19.5, 19.4, 12.0, 11.8. 
19
F NMR (376 MHz, CDCl3): δ = -109.9 (m, 4.0 F, p/ap), -
132.2 (m, 2 F, p/ap). ESI-MS, positive mode: m/z (rel. int., %) = 1166.2 (100) [M+Na]
+
 (found), 





Compound 8 was synthesized from compound S8 (18 mg, 15.7 µmol) according to GP C, and 
purified by flash chromatography using a RP-C18 cartridge (system E); 5 mg, 35% yield. ap:p = 
60:40. 
1
H NMR (500 MHz, DMF-d7): δ = 8.71 (br. t, J = 1.6 Hz, 0.6 H, ap), 8.64 (m, 2.4 H, 
p/ap), 8.60 (d, J = 1.8 Hz, 0.6 H, ap), 8.56 (d, J = 1.8 Hz, 0.4 H, ap), 8.53 – 8.48 (m, 1.0 H, 
p/ap), 8.36 (m, 1.0 H, p/ap), 8.33 (dd, J = 1.8 and 8.0 Hz, 0.6 H, ap), 8.29 (dd, J = 1.8 and 8.0 
Hz, 0.4 H, p), 8.23 (m, 1.0 H, p/ap), 8.17 (dd, J = 1.8 and 8.0 Hz, 0.4 H, p), 8.12 (dd, J = 1.8 and 
8.0 Hz, 0.6 H, ap), 8.02 (m, 1.0 H, p/ap, overlaps with the residual proton signals of DMF-d7), 
7.90 (d, J = 8.0 Hz, 0.6 H, ap), 7.86 (d, J = 8.0 Hz, 0.4 H, p), 4.00 (s, 1.8 H, ap), 3.94 (s, 1.2 H, 
p), 2.87 - 2.62 (m, 4.0 H, p/ap, overlaps with the residual proton signals of DMF-d7), 1.42 (m, 
2.4 H, p), 1.09 (m, 3.6 H, ap). 
13
C NMR (126 MHz, DMF-d7): δ = 167.9, 167.5, 159.8, 150.5, 
150.3, 150.2, 150.0, 143.4, 143.2, 142.9, 142.8, 141.0, 140.0, 139.8, 137.6, 137.6, 137.4, 137.4, 
134.7, 134.4, 134.2, 134.0, 133.9, 133.8, 133.8, 133.1, 133.0, 131.3, 130.6 130.5, 130.1, 129.6, 
129.4, 129.2, 129.0, 125.8, 123.9, 123.9, 122.4, 122.3, 122.2, 121.9, 121.9, 64.2, 64.1, 20.1, 20.0, 
12.7, 12.5, 12.5, 12.4. 
19
F NMR (471 MHz, DMF-d7): δ = -109.7 (m, 4.0 F, p/ap), -130.8 (m, 2.0 
F, p/ap). HR-MS (ESI, positive mode):  941.0748 [M+Na]
+
 (found), 941.0768 (calculated for 
C42H28F6NaO13S2, [M+Na]
+
). HPLC (system A): tR = 13.1 min (4% peak area, closed form), 13.7 
min (96% peak area, open form). 
Compound S9 
 
Compound S9 was synthesized from 1,2-bis(2-ethyl-6-iodobenz[a]thiophen-3-
yl)perfluorocyclopentene
4
 (100 mg, 0.134 mmol) according to GP A1, and purified by column 
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chromatography on silica gel gel (n-hexane/EtOAc, with a gradient from 100:0 to 70:30); 42 mg, 
25% yield. This compound was used in the next step without further purification (HPLC area of 
the main peak 85%). Rf (n-hexane/EtOAc, 4:1, v/v) = 0.5. HR-MS (ESI, positive mode): 
1263.2767 [M+Na]
+





Compound S10 was synthesized from compound S9 (39 mg, 24.2 µmol) according to GP A2, 
and purified by column chromatography on silica gel gel (n-hexane/EtOAc, with a gradient from 
100:0 to 60:40); 20 mg, 53% yield. Rf (n-hexane/EtOAc, 4:1, v/v) = 0.35. ap:p = 70:30. 
1
H NMR 
(400 MHz, CDCl3): δ = 7.92 (d, J = 1.6 Hz, 0.7 H, ap), 7.88 (d, J = 1.6 Hz, 0.7 H, ap), 7.83 (d, J 
= 1.6 Hz, 0.3 H, p), 7.79 (m, 1.0 H, p/ap), 7.78 (d, J = 1.6 Hz, 0.3 H, p), 7.71 (d, J = 2.2 Hz, 0.7 
H, ap), 7.69 (m, 1.3 H, p/ap), 7.65-7.54 (m, 4.0 H, p/ap), 7.50 – 7.38 (m, 2.0 H, p/ap), 7.00 (d, J 
= 8.8 Hz, 1.4 H, ap), 7.93 (d, J = 8.8 Hz, 0.6 H, p), 4.21 (s, 1.1 H, ap), 4.20 (s, 1.1 H, ap) 4.18 (s, 
0.4 H, p), 4.16 (s, 0.4 H, p), 3.99 (s, 2.7 H, p/ap), 3.93 (s, 1.0 H, p/ap), 3.86 (s, 2.0 H, p/ap),  3.81 
(s, 0.8 H, p/ap), 2.95 - 2.74 (m, 2.6 H, p/ap), 2.45 (m, 1.4 H, p/ap), 1.50 (s, 13.0 H, ap), 1.48 (s, 
5.0 H, p), 1.37 (s, 13.0 H, ap), 1.32 (m, 1.8 H, p), 1.27 (s, 5.0 H, p),  0.84 (m, 4.2 H, ap). 
13
C 
NMR (126 MHz, CDCl3): δ = 171.5, 168.7, 168.6, 168.3, 168.2, 159.8, 159.7, 152.3, 151.0, 
142.0, 142.0 ,139.4, 139.4, 139.3, 139.2, 138.6, 137.9, 137.9, 137.4, 137.0, 136.9, 135.8, 135.8, 
133.5, 133.5, 128.8, 128.7, 127.5, 127.5, 124.5, 124.5, 124.4, 124.3, 124.2, 124.0, 123.0, 123.0, 
122.8, 122.7, 122.5, 121.1, 121.0, 120.4, 120.3, 118.2, 118.1, 114.8, 114.7, 83.4, 83.3, 82.6, 82.6, 
55.9, 55.8, 52.9, 52.8, 48.9, 28.6, 28.6, 28.4, 28.2, 23.9, 23.6, 23.5, 16.5, 16.4, 16.0, 15.8. 
19
F 
NMR (376 MHz, CDCl3): δ = -110.3 (m, 4.0 F, p/ap), -132.8 (m, 2.0 F, p/ap). HR-MS (ESI, 
positive mode): 1243.4219 [M+Na]
+








Compound S11 was prepared from S10 (20 mg, 16.4 µmol) according to GP B, and purified by 
column chromatography on silica gel gel (n-hexane/EtOAc, with a gradient from 100:0 to 60:40) 
18 mg, 86% yield. Rf (n-hexane/EtOAc, 4:1, v/v) = 0.28. ap:p = 60:40. 
1
H NMR (400 MHz, 
CDCl3): δ = 8.06 (bt, J = 1.8 Hz, 0.6 H, ap), 7.98 (bt, J = 1.8 Hz, 0.4 H, p), 7.96 (d, J = 1.7 Hz, 
0.6 H, ap), 7.93 (d, J = 1.7 Hz, 0.4 H, p), 7.88 (d, J = 1.7 Hz, 0.6 H, ap), 7.85 (d, J = 1.7 Hz, 0.6 
H, ap), 7.84 (d, J = 1.7 Hz, 0.4 H, p), 7.82 (d, J = 1.7 Hz, 0.4 H, p), 7.78 (m, 1.6 H, p/ap), 7.75 
(d, J = 1.7 Hz, 0.4 H, p), 7.70 (d, J = 1.5 Hz, 0.6 H, ap), 7.66 (dd, J = 1.7 Hz & 8.0 Hz, 0.4 H, p), 
7.62 – 7.60 (m, 3.0 H, p/ap), 7.45 (m, 1.0 H, p/ap), 7.01 (d, J = 8.8 Hz, 1.2 H, ap), 6.96 (d, J = 
8.8 Hz, 0.8 H, p), 4.18 (m, 4.4 H, p/ap), 3.96 (s, 2.6 H, ap), 3.90 (s, 1.0 H, p), 3.87 (s, 1.8 H, ap), 
3.83 (s, 1.2 H, p), 2.68 - 2.52 (m, 3.0 H, p/ap), 2.43 – 2.35 (m, 1.0 H, p/ap), 1.50 (s, 11.0 H, ap), 
1.48 (s, 7.0 H, p), 1.41 (m, 13.4 H, p/ap), 1.32 (s, 7.0 H, p), 1.07 (m, 3.6 H, ap). 
13
C NMR (126 
MHz, CDCl3): δ = 170.7, 168.3, 168.2, 167.8, 167.8, 160.6, 160.6, 149.4, 149.1, 148.2, 147.8, 
144.3, 142.2, 142.1, 139.1, 139.1, 137.2, 137.1, 137.0, 137.0, 136.6, 136.5, 134.8, 133.8, 132.4, 
132.1, 131.6, 131.3, 131.2, 130.5, 130.4, 130.3, 130.0, 129.2, 128.4, 128.4, 128.4, 125.3, 125.1, 
123.5, 123.4, 123.2, 123.1, 123.0, 122.8, 120.9, 120.7, 120.6, 114.9, 114.8, 83.3, 83.2, 82.4, 55.6, 
55.5, 52.6, 52.5, 48.6 48.6, 28.3, 28.3, 28.1, 28.0, 19.5, 19.4, 19.3, 19.2, 12.1, 12.0, 11.9, 11.7. 
19
F NMR (376 MHz, CDCl3): δ = -109.9 (m, 4.0 F, p/ap), -132.3 (m, 2.0 F, p/ap). HR-MS (ESI, 
positive mode): 1307.4004 [M+Na]
+






Compound 10 was prepared from S11 (18 mg, 14.0 µmol) according to GP C, and purified by 
flash chromatography using a RP-C18 cartridge (system E); 7 mg, 47% yield). ap:p = 60:40. 
1
H 
NMR (500 MHz, DMF-d7): δ = 8.49 (d, J = 1.8 Hz, 0.6 H, ap), 8.38 (m, 1.0 H, p/ap), 8.23 (m, 
0.8 H, p/ap), 8.17 (dd, J = 8.1 and 1.8 Hz, 0.6 H, ap), 8.11 (dd, J = 8.0 and 1.8 Hz, 0.4 H, ap), 
8.03 – 7.94 (m, 2.6 H, p/ap, overlaps with the signal of the residual CH-protons in DMF-d7), 
7.89 (m, 2.0 H, p/ap), 7.84 (m, 1.0 H, p/ap), 7.79 (d, J = 8.1 Hz, 0.4 H, p), 7.74 (d, J = 8.1 Hz, 
0.6 H, ap), 7.55 (br. t, J = 1.5 Hz, 0.6 H, ap), 7.51 (br. t, J = 1.5 Hz, 0.4 H, ap), 7.14 (d, J = 8.9 
Hz, 1.2 H, ap), 7.05 (d, J = 8.9 Hz, 0.8 H, p), 4.36 (s, 2.5 H, ap), 4.35 (m, 1.5 H, p), 4.33 (s, 2.5 
H, ap), 4.27 (s, 1.5 H, p), 3.90 (s, 1.7 H, ap), 3.85 (s, 1.3 H, p), 2.85 – 2.70 (m, 2.5 H, p/ap, 
overlaps with the signal of the residual CH3-protons in DMF-d7), 2.61 (m, 1.5 H, p/ap), 1.41 (m, 
2.5 H, p), 1.03 (m, 3.5 H, ap). 
13
C NMR (126 MHz, DMF-d7): δ = 172.4, 171.8, 171.7, 171.5, 
162.0, 161.9, 150.7, 150.4, 149.6, 149.5, 144.9, 143.6, 143.4, 139.9, 139.8, 138.7, 138.6, 137.8, 
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137.8, 137.6, 137.5, 134.8, 134.4, 133.4, 133.1, 131.2, 131.1, 129.9, 129.8, 129.8, 129.7, 128.2, 
127.9, 127.9, 126.7, 126.6, 126.3, 126.0, 125.8, 124.3, 124.2, 122.3, 122.1, 121.2, 121.1, 116.0, 
115.9, 56.4, 56.4, 53.1, 53.0, 49.3, 49.2, 20.3, 20.3, 20.1, 20.1, 13.0, 12.9, 12.7, 12.6. 
19
F NMR 
(471 MHz, DMF-d7): δ = -109.7 (m, 4.0 F, p/ap), -130.7 (m, 2.0 F, p/ap). HR-MS (ESI, negative 
mode): 1059.1510 [M-H]
-
 (found), 1059.1545 (calculated for C48H37F6N2O15S2, [M-H]
-
). HPLC 
(system A): tR = 15.4 min (90% peak area, open form); 16.7 min (2% peak area, closed form). 
Compound S12 
 
Compound S12 was prepared from S9 (90 mg, 72.5 µmol) according to GP A2, and purified by 
column chromatography on silica gel gel (n-hexane/EtOAc, with a gradient from 100:0 to 60:40) 
83 mg, 65% yield. Rf (n-hexane/EtOAc, 3:2, v/v) = 0.52. ap:p = 70:30. 
1
H NMR (400 MHz, 
CDCl3): δ = 7.92 (d, J = 1.7 Hz, 0.7 H, ap), 7.84 (m, 0.6 H, p), 7.79 (d, J = 1.6 Hz, 1.4 H, ap), 
7.72 - 7.43 (m, 6.0 H, p/ap), 7.40 - 7.29 (m, 1.6 H, p/ap), 7.11 - 7.04 (m, 0.7 H, p/ap), 4.64 - 4.45 
(m, 2.0 H, p/ap), 4.26 - 4.15 (m, 3.0 H, p/ap), 4.07 - 3.80 (m, 14.0 H, p/ap), 3.00 - 2.62 (m, 2.0 
H, p/ap), 2.47 - 2.33 (m, 1.5 H, p/ap), 1.51 - 1.46 (m, 36.0 H, p/ap), 1.42 - 1.30 (m, 37.6 H, 
p/ap), 0.90 - 0.80 (m, 4.4 H, ap). 
13
C NMR (126 MHz, CDCl3): δ = 171.0, 169.2, 168.2, 168.0, 
168.0, 167.9, 167.8, 167.8, 151.4, 141.5, 138.9, 138.9, 138.1, 136.5, 135.3, 129.8, 127.1, 124.0, 
123.7, 122.5, 122.4, 120.6, 117.6, 82.9, 82.1, 82.1, 81.9, 52.4, 51.6, 51.6, 48.4, 23.0, 23.0, 15.4, 
15.4. 
19
F NMR (471 MHz, CDCl3): δ = -110.2 (m, 4.0 F, p/ap), -132.9 (m, 2.0 F, p/ap). HR-MS 
(ESI, positive mode): 1785.7057 [M+Na]
+







































Compound S13 was synthesized from S12 (70 mg, 39.7 µmol) according to GP B, and purified 
by column chromatography on silica gel gel (n-hexane/EtOAc, with a gradient from 100:0 to 
60:40); 36 mg, 50% yield. Rf (n-hexane/EtOAc, 3:2, v/v) = 0.45. ap:p = 65:35. 
1
H NMR (400 
MHz, CDCl3): δ = 8.03 - 7.70 (m, 6.35 H, p/ap), 7.66 - 7.47 (m, 3.65 H, p/ap), 7.28 - 7.19 (m, 
1.0 H, p/ap, overlaps with the signal of the residual CH-protons in CDCl3), 4.61 - 4.41 (m, 2.0 
H, p/ap), 4.26 - 4.13 (m, 4.0 H, p/ap), 4.05 - 3.81 (m, 13.0 H, p/ap), 2.67 - 2.47 (m, 2.4 H, p/ap), 
2.39 - 2.26 (m, 1.6 H, p/ap), 1.52 - 1.44 (m, 38.0 H, p/ap),  1.40 - 1.28 (m, 36 H, p/ap), 1.07 - 
0.97 (m, 4.0 H, ap). 
19
F NMR (376 MHz, CDCl3): δ = -109.8 (m, 4.0 F, p/ap), -132.2 (m, 2.0 F, 
p/ap). HR-MS (ESI, positive mode): 1849.6860 [M+Na]
+






3. Immunolabeling and fluorescence imaging   
3.2 Photoswitching of bioconjugates 
To ensure that the DAEs bound to proteins were still photochemically active, diluted samples (in 
MeOH and PBS; pH = 7.4) of the bioconjugates were placed into a 1 cm path quartz cuvette and 
irradiated under conditions similar to the conditions used for photoswitching of the free dyes, in 
MeOH and PBS. Photoisomerizations of the probes in both directions (with 365 nm light 
(OF→CF) and 470 nm (CF→OF) light) were observed, with the concomitant changes in 
fluorescence emission (Figure S1). 
 
Figure S1. Absorption and emission changes upon irradiation of two representative bioconjugates of 4-Et (DOL = 
3, A) and 11 (DOL = 5, B) in PBS (pH = 7.4). Diluted samples in a 1 cm-path quartz cuvette were irradiated under 
continuous stirring. Typical irradiation light powers were around 20−30 mW. Absorption and emission spectra were 
recorded after each irradiation step (10−60 s). 
 
3.3 Immunolabeling protocol 
Vero cell samples cells were grown on standard cover slips and then fixed with previously 
cooled (-20 °C) methanol for 5 min, and blocked with 5% (w/v) BSA in PBS pH = 7.4 (blocking 
buffer). Then the cells were incubated with a primary antibody at r.t. for 1 h, followed by three 
washing steps of 5 min each with blocking buffer. The cells were then incubated at r.t. for 1 h 
with the labelled bioconjugates (typical dilutions of 1:50 to 1:100 from the purified 
bioconjugate), washed again (5 min each step) three times with blocking buffer and, finally, with 
mounting medium (PBS, pH 7.4). The samples were mounted with PBS (pH = 7.4) in concave 
microscopy slides and sealed with a silicone resin (Picodent Twinsil) to prevent leakage. As 
primary antibodies (Abcam, Cambridge, UK), mouse and rabbit anti-α-tubulin, mouse anti-NUP 





3.4 Confocal images  
Standard confocal images were acquired in a commercial Leica TCS SP5 confocal microscope. 
Images (Figures S2 and S3) were recorded with 488 nm excitation, after a short (ca. 1-5 s) and 
low- intensity wide-field pre-activation with ~366 nm light, from the mercury lamp. Detection 
was collected between 520 and 670 nm. A fading of the signal was observed after one or several 
consecutive scans of the same area, due to the isomerization (CF→OF) induced by the excitation 
light (a process competing with fluorescence emission of the probe). The signal can be recovered 
with another pre-activation pulse, and thus further imaging of the same area can be repeated 
several times. 
 
Figure S2. Confocal imaging with a 4-Et bioconjugate. First, an overview of a cell was recorded (A). Then, an 
image of the ROI (boxed area in A) was acquired (B). The pixel size in B is smaller than in A, C-D, and thus 
markers received a higher light dose. The following overview image (C) shows the fading of the signal in the ROI. 
The signal is recovered (D) after a short exposition (a few seconds) to UV light (wide-field illumination of a Hg 
lamp selected with a filter), which demonstrates that the fading was due to the cycloreversion of the DAE markers. 
 
Figure S3. Confocal imaging with a 11 bioconjugate. A total of 17 frames were successively acquired on the same 
FOV (frames 1, 5, 9, 13, and 17 are shown). The sample was then exposed for a few seconds to UV light (wide-field 
illumination of a Hg lamp selected with a filter), and a new frame was acquired. Exact same imaging settings were 
used for all frames. 
  
24
3.5 Superresolution (PALM/STORM) imaging 
 
3.5.1 STORM Microscope: 
The microscope (Figure S4) is based on a commercial microscope stand (Olympus IX71) and 
imaging was carried out using a 100 x 1.4 NA oil-immersion objective (OB: Olympus 
UPLSAPO 100XO).  Excitation light sources included a 488 nm Argon laser (L 488: Innova 70C 
Argon filled, Coherent, ~0.5 kW/cm²), and a 375 nm laser diode (L 375: CUBE 375, Coherent, 
~13 W/cm²). The 488 nm was modulated using an acouto-optic tunable filter (AOTF: PCAOM 
VIS, Crystal Technology).  The 375 nm beam was combined into the excitation beam path after 
the AOTF by a dichroic mirror (Di01-R405-25x36, Semrock), and was modulated using its own 
digital & analog modulation inputs.  The combined beams were expanded and cropped using an 
aperture, in order to achieve a relatively flat illumination profile, before being focused to the 
back focal plane of the objective lens, such that the light beam reaching the sample is collimated. 
The lateral position of the excitation beam focus in the objective was adjusted using a translation 
stage in the excitation beam path, such that the illumination could be brought in to a total-
internal-reflection (TIRF) configuration. 
A quad band dichroic mirror (ZT405/488/561/640rpc, Chroma) was used to separate the 
incoming excitation light from the outgoing fluorescence. The fluorescence was further filtered 
using a quad band notch filter (NF01-405/488/557/640-25x5.0-D, Semrock) and a band-pass 
filter (FF01-582/75-25, Semrock).  The fluorescence image of the sample was relayed through a 
telescope and detected using an EMCCD camera (IXON+ DU860, Andor Technologies). 
Sample focus was maintained during imaging using a custom-built focus lock system.  An infra-
red laser beam was introduced into the microscope through the right side port and coupled into 
the optical path using a dichroic mirror (900SPRDC, Chroma).  The beam was focused to the 
back focal plane of the objective and the focal position was adjusted to bring the beam into TIRF 
at the water-glass interface in the sample. The position of the reflected beam was monitored 
using a quadrant-photodiode and this provided a measure of the sample position above the 
objective lens. The objective lens position was then continuously adjusted using a piezo 
positioner (MIPOS 250, Piezo Jena). Residual infrared light was blocked in the detection path 








3.5.2 Detected photons per switching event 
 
 
Figure S5. Histogram of detected photons per switching event, generated from every single molecule localized and 
used to reconstruct superresolution images presented in the text (Figures 2 – 4). The average values reported for 
each case were calculated from a mono-exponential fit, as in Dempsey et al. (6). When calculating the mean or 






3.5.3 Photoinduced control of the amount of events per frame 
 
 
Figure S6. Superresolution images (STORM) without (A) and with activation light of 375 nm (B), of Vero cells 
immunostained with a primary antibody against tubulin and a secondary antibody labelled with compound 4-Et 
(DOL = 3.5). Mounting media used was PBS pH = 7.4. No photoactivation (only excitation at 488 nm) was used in 
the first 50000 frames; slow photobleaching is evidenced by an exponential decay of the detected events per frame 
(C). Then, the activation laser was enabled at low power and increased stepwise, as indicated by black arrows in (D). 
The activation laser was disabled for ca. 2000 frames (red arrow); spontaneous activations is still present, but at a 
lower rate than in the presence of photoactivation (the latter is ~3-fold higher). At the end of the image acquisition, 
the activation laser was considerable increased beyond the condition to achieve a sparse distribution but enough to 
achieve a wide field image; a frame (only 10 ms integration) is shown in (E). This demonstrates the remaining 




3.6 Photoswitching fatigue resistance of compounds 4-Et and 11 at the 
ensemble level, in methanol and aqueous buffered solutions 
 
Figure S7. Photoswitching fatigue resistance of compounds 4-Et and 11 in methanol and aqueous PBS. Solutions of 
each compound (OF) were freshly prepared (c0 = 4-5 µM = [OF] + [CF]). The samples (3 mL) were irradiated under 
continuous stirring with UV light (365 nm), until 85-90% conversion to the CF (αCF = [CF]/c0 > 0.85) was achieved, 
and then irradiated with visible light (470 nm), until the reaction was reversed to a conversion below 10 % (αCF < 
0.10). The intensity of the irradiation sources (20 mW/cm
2
 and 35 mW/cm
2
 for UV and visible light, respectively) 
was the same in all experiments. The time required for each semi-cycle was found (tUV = 3 – 20 min and tVIS = 33 – 
80 min) and used for repeating the photoconversion for 14 full cycles (in total, 8 – 23 hours of irradiation was 
required for each solution). The degree of conversion was evaluated by measuring the absorption of the closed form 
in the visible range using a single beam spectrometer. The amount of compound irreversibly photobleached after 14 
cycles was very similar for both compounds, and amounted to 7% in methanol, and 15 % in PBS (±2%). From this 
experiment, we can conclude that these compounds can endure in average several tens of cycles, determined from 
the number of cycles needed to photobleach half of the initial dye amount. 
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3.7 Fourier ring correlation analysis of the images 
 
Figure S8. Fourier ring correlation (FRC) of the localizations presented in Figure 2; a smoothed FRC curve is 
shown as a solid blue line within the noisy FRC data (blue dots). The resolution of the image is estimated from the 
intersection between the FRC and the 2σ threshold, yielding a value of around 90 nm. 
 
3.8 Imaging in “blinking buffer” 
 
Figure S9. Superresolution images (STORM) of Vero cells immunolabeled with primary antibody against tubulin 
and secondary antibodies conjugated with compound 4-Et in (A) PBS pH = 7.4 and (B-C) in blinking buffer without 
UV activation. The image in B is the same as in C, with a saturated colormap. The blinking buffer (TRIS pH = 8.0) 
contained an enzymatic oxygen scavenger system and β-mercaptoethylamine. Scale-bars: 1 µm. 
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4. NMR spectra and RP-HPLC traces of symmetric dimethoxy 
DAEs derivatives: compounds 3, 4-Me and 4-Et 
Compound 3 
1





C NMR spectrum in CDCl3 (500 MHz) 
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RP-HPLC elution profile (system F); “open-ring” isomer – red trace (254 nm), “closed-ring” 
isomer – blue trace (470 nm): 
 
RP-HPLC elution profile (system F); “closed-ring” isomer showing green trace (254 nm) and 




RP-HPLC elution profile (system F): “closed-ring” isomer in CD3OD solution after storing for 3 
weeks in the dark at room temperature; relative intensities of the red (254 nm) and blue (470 nm) 



















C NMR spectrum in CDCl3 (101 MHz) 
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C NMR spectrum in CDCl3 (101 MHz) 
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C NMR spectrum in DMF-d7 (126 MHz) 
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C NMR spectrum in DMF-d7 (126 MHz) 
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C NMR spectrum in CDCl3 (101 MHz) 
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H NMR spectrum in DMF-d7 (500 MHz)  *,** peaks assigned to residual solvent (DCM, CH3CN) 
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C NMR spectrum in DMF-d7 (126 MHz) 
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RP-HPLC elution profile (system F); “open-ring” isomer – red trace (254 nm); “closed-ring” 
isomer – blue trace (470 nm): 
 
RP-HPLC elution profile (system F); “closed-ring” isomer, which shows green trace (254 nm) 
and black trace (470 nm), was isolated by HPLC and immediately analyzed in CD3OD: 
 
RP-HPLC elution profile (system F): “closed-ring” isomer dissolved in CD3OD after storing for 
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